Menu +

Tag: paul-ehrlich-institut

New Clinical Trial for a COVID-19 Vaccine Authorised in Germany

The Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines has authorised another Phase-1 clinical trial of a vaccine against COVID-19 in Germany. The new vaccine candidate is a so-called vector vaccine. Trials on vaccine candidates in humans are a significant step in the direction of authorising safe and efficacious vaccines against COVID-19. This new vaccine is […]

Influenza Season 2020/21 – First Vaccine Batches Released

The Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines started the annual batch release testing of influenza vaccines on 31 July 2020. In the meantime, the first 13,6 million doses have been released for German market. The batch testing is based on the strain adaptations approved by the Federal Institute or the EU Commission for the […]

SARS-CoV-2 Immunogenity at the Crossroads

photo Jason McLellan / University of Texas, Austin

The current coronal virus 2 pandemic presents a world-wide health risk. Researchers at the Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines (PEI) have summarised the latest findings on the function, structure, and immunogenicity of the spike protein (surface protein of the virus) as well as occurring mutations and the significance for the development of vaccines […]